We are live on ! Find out more
SPRB

Spruce Biosciences
SPRB

38 hedge funds and large institutions have $72M invested in Spruce Biosciences in 2023 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 10 increasing their positions, 8 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

25% more repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 8

5% more capital invested

Capital invested by funds: $68.7M → $72M (+$3.25M)

0% more funds holding

Funds holding: 38 → 38 (0)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

0% more first-time investments, than exits

New positions opened: 1 | Existing positions closed: 1

Holders
38
Holders Change
–
Holders Change %
0%
% of All Funds
0.6%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
1
Increased
10
Reduced
8
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
DCM
DAFNA Capital Management
California
+$580K
2
Verition Fund Management
Verition Fund Management
Connecticut
+$530K
3
ACM
AIGH Capital Management
Maryland
+$225K
4
Vanguard Group
Vanguard Group
Pennsylvania
+$149K
5
WVP
Worth Venture Partners
New Jersey
+$54.9K

Top Sellers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
-$993K
2
Two Sigma Advisers
Two Sigma Advisers
New York
-$323K
3
Two Sigma Investments
Two Sigma Investments
New York
-$182K
4
Geode Capital Management
Geode Capital Management
Massachusetts
-$113K
5
Renaissance Technologies
Renaissance Technologies
New York
-$70.4K
Name Holding Trade Value Shares
Change 		Change in
Stake
NHAS
1
Novo Holdings A/S
Denmark
$15.2M – – –
AC
2
Armistice Capital
New York
$6.91M -$993K -5,893 -13%
RVM
3
RiverVest Venture Management
Missouri
$6.64M – – –
CG
4
Carlyle Group
District of Columbia
$6.46M – – –
RSCM
5
Rock Springs Capital Management
Maryland
$6.17M – – –
5VM
6
5AM Venture Management
California
$5.34M – – –
OFM
7
Omega Fund Management
Massachusetts
$4.88M – – –
Verition Fund Management
8
Verition Fund Management
Connecticut
$2.98M +$530K +3,142 +22%
ACM
9
AIGH Capital Management
Maryland
$2.74M +$225K +1,334 +9%
ACM
10
Aisling Capital Management
New York
$2.72M – – –
Alyeska Investment Group
11
Alyeska Investment Group
Illinois
$2.26M – – –
SCV
12
Sands Capital Ventures
Virginia
$1.78M – – –
Millennium Management
13
Millennium Management
New York
$1.32M +$13.1K +78 +1%
DCM
14
DAFNA Capital Management
California
$1.29M +$580K +3,442 +83%
Vanguard Group
15
Vanguard Group
Pennsylvania
$742K +$149K +884 +25%
WVP
16
Worth Venture Partners
New Jersey
$683K +$54.9K +326 +9%
AI
17
Acuitas Investments
Washington
$622K – – –
BlackRock
18
BlackRock
New York
$584K -$5.56K -33 -0.9%
Renaissance Technologies
19
Renaissance Technologies
New York
$470K -$70.4K -418 -13%
Geode Capital Management
20
Geode Capital Management
Massachusetts
$378K -$113K -673 -23%
Two Sigma Investments
21
Two Sigma Investments
New York
$333K -$182K -1,077 -35%
Two Sigma Advisers
22
Two Sigma Advisers
New York
$218K -$323K -1,916 -60%
Bank of New York Mellon
23
Bank of New York Mellon
New York
$201K -$5.22K -31 -3%
BCM
24
Bridgeway Capital Management
Texas
$192K – – –
Citadel Advisors
25
Citadel Advisors
Florida
$170K +$8.43K +50 +5%
1
2

SPRB Hedge Fund Activity: Q3 2023 in Review

38 of the 6,304 institutional investors tracked by Wall St. Rank reported a position in Spruce Biosciences (SPRB) for Q3 2023, worth a combined $72M — up 4.7% from $68.7M a quarter earlier.

Fund positioning in SPRB was balanced in Q3 2023: 1 fund opened new positions, 1 closed out, 10 added to existing stakes and 8 trimmed.

The largest buyer was DAFNA Capital Management, adding an estimated $580K. The largest seller was Armistice Capital, cutting an estimated $993K.

  • 38 institutional investors held Spruce Biosciences (SPRB) as of Q3 2023, unchanged from Q2 2023.
  • Funds reported $72M of Spruce Biosciences stock for Q3 2023, up 4.7% quarter-over-quarter.
  • 1 fund opened new Spruce Biosciences positions in Q3 2023 and 1 closed out, a net change of 0 holders.
  • The largest Spruce Biosciences buyer in Q3 2023 was DAFNA Capital Management, an estimated $580K added.
  • The largest Spruce Biosciences seller in Q3 2023 was Armistice Capital, an estimated $993K sold.

Based on aggregated 13F filings for Q3 2023.